Industry association · Austria · EU Transparency Register 098025935611-30
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Among the 1518 trade and business associations on this site, they rank #512 by legislative files engaged, a count of participation, not a measure of influence.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track PHARMIG in PolicySpeak: request access →
Work at PHARMIG - Verband der pharmazeutischen Industrie Österreichs? so we know who speaks for it.
PHARMIG - Verband der pharmazeutischen Industrie Österreichs filed 9 positions between 23 Dec 2020 and 31 Jul 2026, across 6 of the 665 legislative files tracked here, attaching a full position paper 3 times.
PHARMIG welcomes the European Commission’s (EC) Digital Omnibus package as an important opportunity to create more coherence and legal certainty in the EU’s digital rulebook. Data is a critical enabler for pharmaceutical research, development and production, as well as for the use of AI-based applications throughout the lifecycle of medicines.
Filed in German · English published by the European Commission
The PHARMIG with the support of FOPI and ÖVIH – welcomes the European Commission’s objectives. The revision is an opportunity to strengthen Europe as a pharmaceutical site. Nevertheless, some of the proposed measures imply legal uncertainty for businesses and diametrically counter the stated objectives of improving patient access to medicines, fostering innovation and international competitiveness.
Filed in German · English published by the European Commission
The PHARMIG with the support of FOPI and ÖVIH – welcomes the European Commission’s objectives. The revision is an opportunity to strengthen Europe as a pharmaceutical site. Nevertheless, some of the proposed measures imply legal uncertainty for businesses and diametrically counter the stated objectives of improving patient access to medicines, fostering innovation and international competitiveness.
Filed in German · English published by the European Commission
Phare is in favour of an agile regulatory framework and an attractive incentive system to support and promote progress in science, technology and medicine. Adequate conditions need to be put in place to support a sustainable market for pharmaceuticals (AM) in order to strengthen the supply and production of this AM in the EU.
Filed in German · English published by the European Commission
PHARMIG, the Austrian Pharmaceutical Industry Association, welcomes in principle the European Commission’s proposal on the European Biotech Act I (Proposal for a Regulation of the European Parliament and of the Council establishing a framework of measures for strengthening biotechnology and biomanufacturing in the Union, in particular in the field of health, and amending Regulations (EC) No 178/2002, (EC) No…
Filed in German · English published by the European Commission
PHARMIG, the voluntary representation of the Austrian pharmaceutical industry, strongly supports the objective of the announced European Biotech Act: Creating a world-class innovation environment for biotechnologies! Among other things, PHARMIG is working to maximise the potential of the competitive pharmaceutical sector.
Filed in German · English published by the European Commission
The creation of a system of incentives within these Regulations have been identified as the essential and target-oriented measures to increase research and development for rare diseases and children in the EU. And indeed, the evaluation of the Regulations found that both Regulations fostered the development and availability of medicines in these areas.
Without the robust IP system, significant investments in R & D in novel technologies, vaccines, therapeutic & other products, including COVID-19, would not have taken place over the last decades. IP is a key tool to promote innovation and secure high-risk and high-cost investments for this purpose.
Filed in German · English published by the European Commission
The supply of innovative products such as medicines is a complex, time-consuming and financially risky process. The patent system guarantees investment protection in return for the provision of the knowledge acquired.
Filed in German · English published by the European Commission
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put PHARMIG - Verband der pharmazeutischen Industrie Österreichs next to another organization. Same files, same register facts, side by side. Compare →
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 132.
Everything on this page comes from PHARMIG - Verband der pharmazeutischen Industrie Österreichs’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.